Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CVM Updates

CVM Updates Home
          Animal & Veterinary
          News & Events
          CVM Updates
          FDA Approves First Treatment for Giardia duodenalis in Any Animal SpeciesCVM Updates FDA Approves First Treatment for Giardia duodenalis in Any Animal Species
  
  	
    Share
    Post
    Linkedin

    Email
    Print**October 25, 2023**: This page has been edited to clarify that Ayradia (metronidazole) is only approved for use in dogs and that this product represents the first FDA-approved animal drug for treating *Giardia duodenalis* infections.


October 11, 2023

Today the U.S. Food and Drug Administration approved Ayradia (metronidazole oral suspension) for the treatment of *Giardia duodenalis* infection in dogs. Ayradia is the first FDA-approved animal drug for treating *Giardia duodenalis* infections.

*Giardia duodenalis* is a common protozoal parasite that can infect the intestinal tract in dogs. Although *Giardia*can be present in healthy dogs, it can also lead to gastrointestinal infections that most commonly cause diarrhea, which can sometimes be severe. *Giardia*can be spread to other animals and is also a protozoal parasite with zoonotic potential, meaning it can spread to people.

Metronidazole has both anti-bacterial and anti-protozoal activities. Although veterinarians have historically prescribed a metronidazole product intended for humans when treating their animal patients for *Giardia duodenalis*, today’s approval means there is an approved product for dogs that has known safety and effectiveness for this species and is manufactured to quality standards.

The sponsor conducted a laboratory study and a field study to demonstrate the effectiveness of Ayradia to treat *Giardia*infections. In both studies, Ayradia effectively reduced the post-treatment counts of the *Giardia*parasite in treated dogs.

The most common adverse events in dogs treated with Ayradia were vomiting and diarrhea, which resolved without treatment.

Ayradia is only available by prescription from a licensed veterinarian because professional expertise is required to properly diagnose *Giardia duodenalis* infection in dogs and to monitor the safe use of the product, including treatment of any adverse reactions.

People with known sensitivity to metronidazole or other nitroimidazole products should avoid contact with Ayradia. Ayradia is a skin sensitizer, which can potentially cause allergic reactions. In case of skin contact, the affected area should be washed thoroughly. People who come in contact with a treated dog’s saliva during the first five minutes after administration should wash their hands. Although it is a best practice to always keep dog food away from children, pet owners should be particularly careful to keep dog food that has been mixed with Ayradia away from children.

Ayradia is administered orally at 25 mg/kg (11.3 mg/lb) of body weight, using the supplied syringe, twice daily for five consecutive days.

Ayradia is sponsored by Virbac AH, Inc., based in Fort Worth, Texas.

For more information:

Freedom of Information summary**Issued by FDA Center for Veterinary Medicine.
For questions, Contact CVM.**

                                                                                  Content current as of:
      10/25/2023CVM Updates
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop